Biosergen Financial Statements From 2010 to 2026
| BIOSGN Stock | 41.60 1.60 4.00% |
Check Biosergen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biosergen's main balance sheet or income statement drivers, such as , as well as many indicators such as . Biosergen financial statements analysis is a perfect complement when working with Biosergen Valuation or Volatility modules.
Biosergen |
Biosergen AS Company Price To Book Analysis
Biosergen's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Biosergen Price To Book | 6.55 X |
Most of Biosergen's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biosergen AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Based on the latest financial disclosure, Biosergen AS has a Price To Book of 6.5472 times. This is much higher than that of the sector and significantly higher than that of the Price To Book industry. The price to book for all Sweden stocks is notably lower than that of the firm.
Biosergen AS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biosergen's current stock value. Our valuation model uses many indicators to compare Biosergen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biosergen competition to find correlations between indicators driving Biosergen's intrinsic value. More Info.Biosergen AS is rated below average in operating margin category among its peers. It is rated below average in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Biosergen by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Biosergen's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Biosergen Financial Statements
Biosergen stakeholders use historical fundamental indicators, such as Biosergen's revenue or net income, to determine how well the company is positioned to perform in the future. Although Biosergen investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biosergen's assets and liabilities are reflected in the revenues and expenses on Biosergen's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biosergen AS. Please read more on our technical analysis and fundamental analysis pages.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Biosergen Stock
Biosergen financial ratios help investors to determine whether Biosergen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biosergen with respect to the benefits of owning Biosergen security.